Myasthenia Gravis Treatment Global Market Report 2024

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the preceding timeframe can be credited to the adoption of cholinesterase inhibitors, advancements in thymectomy procedures, the implementation of immunosuppressive therapies, the introduction of plasma exchange, and heightened patient advocacy efforts.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the upcoming period is linked to factors such as the increased use of biologics and monoclonal antibodies, advancements in genetic and precision medicine, the rise of emerging immune modulators, and the implementation of neuroprotective strategies and biosimilar medications. Key trends expected during the forecast period encompass the adoption of digital therapeutics, collaborative research initiatives, patient-centric approaches, the utilization of real-world evidence, and the implementation of long-term safety monitoring.

The anticipated increase in the prevalence of myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis, characterized by autoimmune neuromuscular challenges leading to fatigue and weakness in skeletal muscles, necessitates comprehensive healthcare services for effective management. The surge in myasthenia gravis cases is contributing to heightened sales within the myasthenia gravis treatment market. For instance, data from the National Organization for Rare Disorders, a US-based non-profit supporting individuals with rare diseases, revealed an estimated prevalence of 14–40 cases per 100,000 individuals in the United States in January 2022. Similarly, a study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia in December 2021 estimated a global prevalence of 12.4 people per 100,000 for myasthenia gravis. Consequently, the increasing prevalence of myasthenia gravis is a significant driver of growth in the myasthenia gravis treatment market.

The growth of the myasthenia gravis treatment market is being propelled by the rise in healthcare spending. Healthcare spending, denoting the total financial resources allocated to the healthcare sector within a specific region, country, or organization, is crucial for addressing autoimmune neuromuscular disorders such as myasthenia gravis. This financial commitment ensures optimal patient care, effective symptom management, and an overall enhanced quality of life. For instance, according to the American Medical Association in March 2023, health spending in the United States witnessed a 2.7% increase in 2021, reaching $4.3 trillion, equivalent to $12,914 per capita. Consequently, the upward trajectory in healthcare spending is a key factor driving the growth of the myasthenia gravis treatment market.

The myasthenia gravis treatment market is witnessing a prominent trend towards product innovations, with major companies actively engaged in the development of novel solutions to enhance their market standing. A case in point is Argenx SE, a Netherlands-based biopharmaceutical company, which secured approval from the U.S. Food and Drug Administration (FDA) in December 2021 for its groundbreaking drug, VYVGARTô (efgartigimod alfa-fcab). Specifically designed for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis, VYVGART stands out as the first and only FDA-approved neonatal Fc receptor (FcRn) blocker in the realm of generalized myasthenia gravis treatment. Argenx SE has further solidified its market position by entering into agreements in principle with various regional and national commercial payers, establishing value-based agreements to ensure patient access and cost predictability.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In December 2021, Merck, a Germany-based pharmaceutical company, executed the acquisition of Chord Therapeutics, a Switzerland-based pharmaceutical company, for an undisclosed amount. This strategic move empowered Merck by incorporating cladribine into its pipeline and acquiring rights to develop cladribine for generalized myasthenia gravis (gMG). Cladribine, known for its therapeutic impact on B and T cells, key contributors to autoimmune diseases such as generalized myasthenia gravis, expanded Merck’s neuroinflammatory disease portfolio. This acquisition complemented Merck's existing neurology portfolio in multiple sclerosis (MS), reinforcing its presence in the neuroinflammatory disease domain.

Major companies operating in the myasthenia gravis treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics PLC, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Avadel Pharmaceuticals PLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., Zenyaku Kogyo Co. Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics.

North America was the largest region in the myasthenia gravis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

The myasthenia gravis treatment market research report is one of a series of new reports that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.